NGENLA DIN 02521679
Status: Marketed
Holder: PFIZER CANADA ULC
Available to quote
Health Canada record
| Active ingredient(s) | SOMATROGON 20 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | H01AC08 SOMATROGON |
|---|
| Original market date | 22-Feb-2022 |
|---|
| Current status date | 22-Feb-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SOMATROGON
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02521687 | NGENLA | PFIZER CANADA ULC | Solution | SOMATROGON 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 26936 | 2021-10-26 | New Drug Submission (NDS) | |
Request a quote for NGENLA
How to read a Canadian DIN record